secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adicet Bio, Inc. (ACET)
CIK:        0001720580
Form:       8-K
Filed at:   2025-10-07T23:59:59+00:00
Accession:  0001193125-25-232539
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adicet Bio: 100% renal response in Phase 1 ADI-001 lupus nephritis; plans FDA meeting Q1 2026
--------------------------------------------------------------------------------

- Seven patients (5 LN, 2 SLE) dosed; follow-up 2–9 months as of Aug 31, 2025 cut-off.
- All 5 LN patients achieved renal response: 3 complete, 2 partial; all ongoing; 3 also DORIS remission.
- No serious AEs, no ICANS; only Grade 1 CRS (2 patients) and 1 Grade 1 infection; outpatient potential.
- All patients discontinued immunosuppressants; discontinued or tapered corticosteroids to physiological levels.
- Plans to request FDA meeting in Q1 2026 for pivotal Phase 2 trial design; enrollment continues until study opens.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720580/000119312525232539/0001193125-25-232539-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720580/000119312525232539/acet-20251007.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-232539

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer